Ann Arbor, MI, September 13, 2023 — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), will be participating at the Stifel I&I summit, held virtually,…
– Results highlighted in oral presentation show linsitinib significantly limited disease severity in early- and late-stage TED mouse models and prevented development of autoimmune response – – Company currently evaluating linsitinib in ongoing global Phase 2b LIDS clinical trial in…
– Treatment with linsitinib in a clinically relevant mouse model demonstrated a significant reduction in autoimmune response and classical Thyroid Eye Disease (TED) symptoms, independent of TED severity – – Ongoing global Phase 2b LIDS clinical trial evaluating linsitinib for…
– Data demonstrate significant improvements in clinically relevant endpoints including reduced inflammation of fat and muscle behind the eye – – Company evaluating linsitinib in global Phase 2b LIDS clinical trial for treatment of active, moderate to severe thyroid eye…
– First oral IGF-1R inhibitor to enter late-stage clinical trials for thyroid eye disease – – Global study being conducted in the U.S., Canada, UK, and Europe – Ann Arbor, MI, July 25, 2022 — Sling Therapeutics, Inc., a biopharmaceutical…
– Accomplished life sciences executive brings nearly four decades of experience in pharmaceutical and biotechnology drug development and business operations – Ann Arbor, MI, June 27, 2022 — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an…
– Company receives FDA IND clearance for linsitinib and prepares to initiate Phase 2b clinical trial – Ann Arbor, MI, June 13, 2022 — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for…